Does OSIMERTINIB Cause Product dose omission issue? 213 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 213 reports of Product dose omission issue have been filed in association with OSIMERTINIB (TAGRISSO). This represents 0.8% of all adverse event reports for OSIMERTINIB.
213
Reports of Product dose omission issue with OSIMERTINIB
0.8%
of all OSIMERTINIB reports
10
Deaths
96
Hospitalizations
How Dangerous Is Product dose omission issue From OSIMERTINIB?
Of the 213 reports, 10 (4.7%) resulted in death, 96 (45.1%) required hospitalization, and 4 (1.9%) were considered life-threatening.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OSIMERTINIB. However, 213 reports have been filed with the FAERS database.
What Other Side Effects Does OSIMERTINIB Cause?
Death (10,423)
Malignant neoplasm progression (2,920)
Diarrhoea (1,408)
Drug resistance (1,026)
Fatigue (819)
Rash (772)
Decreased appetite (706)
Drug ineffective (627)
Dyspnoea (621)
Nausea (610)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which OSIMERTINIB Alternatives Have Lower Product dose omission issue Risk?
OSIMERTINIB vs OSPEMIFENE
OSIMERTINIB vs OSPHENA
OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB
OSIMERTINIB vs OXACILLIN
OSIMERTINIB vs OXALIPLATIN